<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913285</url>
  </required_header>
  <id_info>
    <org_study_id>KN-8701</org_study_id>
    <nct_id>NCT04913285</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors</brief_title>
  <official_title>A Phase 1/1b Open-Label, Multicenter, Two Part Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kinnate Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kinnate Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      preliminary efficacy of KIN-2787 in adults with BRAF-mutated advanced or metastatic solid&#xD;
      tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BRAF, a gene that helps to control cell growth, is commonly altered in some cancers. BRAF&#xD;
      alterations can be categorized into three classes based on their unique properties. Targeted&#xD;
      therapies have been approved to treat certain types of cancers that harbor BRAF Class I&#xD;
      mutations. However, there are currently no approved BRAF targeted therapies available for&#xD;
      patients with tumors driven by Class II or Class III BRAF alterations&#xD;
&#xD;
      This study will evaluate the safety, pharmacokinetics (PK), and early clinical activity of&#xD;
      KIN-2787, an experimental drug intended to target solid tumors harboring Class I, Class II,&#xD;
      or Class III BRAF alterations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), and incidence of clinically significant changes in vital signs, physical examinations, ECGs, and clinical laboratory tests.</measure>
    <time_frame>Initiation of study drug through 28 days after last dose (up to approximately 18 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part B (dose expansion) - objective response rate (ORR) using RECIST v1.1.</measure>
    <time_frame>Initiation of study drug until disease progression (up to approximately 36 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part B (dose expansion) - disease control rate (DCR).</measure>
    <time_frame>Initiation of study drug until disease progression (up to approximately 36 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part B (dose expansion) - duration of overall response (DOR).</measure>
    <time_frame>Initiation of study drug until disease progression (up to approximately 36 months)</time_frame>
    <description>Measure of clinical benefit, defined as the time from initial tumor response to documented tumor progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In Part B (dose expansion) - duration of stable disease.</measure>
    <time_frame>Initiation of study drug until disease progression (up to approximately 36 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of KIN-2787</measure>
    <time_frame>Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve Cmax (Tmax)</measure>
    <time_frame>Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC).</measure>
    <time_frame>Initiation of study drug through Cycle 5, where each cycle is 28 days (up to approximately 4 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of KIN-2787 in patients with solid tumors harboring Class I, Class II, or Class III BRAF alterations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion evaluating the recommended phase 2 dose (RP2D) of KIN-2787 in patients with NSCLC, melanoma, and other solid tumors harboring Class II or Class III BRAF alterations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KIN-2787</intervention_name>
    <description>KIN-2787 will be administered orally twice daily in 28-day cycles</description>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent prior to initiation of any study-specific procedures.&#xD;
&#xD;
          -  Metastatic or advanced stage solid tumor.&#xD;
&#xD;
          -  Known BRAF Class I, Class II, or Class III alteration as confirmed by previous genomic&#xD;
             analysis of tumor tissue or ctDNA.&#xD;
&#xD;
          -  Must have received prior standard therapy appropriate for the tumor type and stage of&#xD;
             disease (including prior therapy with a BRAF inhibitor if FDA approved for the cancer&#xD;
             type), OR unlikely to tolerate or derive clinically meaningful benefit from&#xD;
             appropriate standard of care therapy.&#xD;
&#xD;
          -  Measurable or evaluable disease by RECIST v1.1.&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2.&#xD;
&#xD;
          -  Adequate organ function, as measured by laboratory values (criteria listed in&#xD;
             protocol).&#xD;
&#xD;
          -  Able to swallow, retain, and absorb oral medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active brain metastases from non-brain tumors.&#xD;
&#xD;
          -  For tumor types and indications not approved by FDA, prior receipt of any BRAF-, MEK-,&#xD;
             or MAPK-directed inhibitor therapy.&#xD;
&#xD;
          -  GI tract disease causing an inability to take oral medication, malabsorption syndrome,&#xD;
             requirement for intravenous alimentation, or uncontrolled inflammatory GI disease.&#xD;
&#xD;
          -  Seropositive for hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Women who are lactating or breastfeeding, or pregnant.&#xD;
&#xD;
          -  In Dose Expansion, patients with BRAF Class I mutations are excluded.&#xD;
&#xD;
        Complete inclusion and exclusion criteria are listed in the clinical study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cynthia Voong</last_name>
    <phone>+1 (619) 614-3663</phone>
    <email>cynthia.voong@kinnate.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xing</last_name>
      <phone>626-218-9200</phone>
      <email>yxing@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Appelt, CCRC</last_name>
      <phone>858-822-0201</phone>
      <email>jappelt@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Lake Nona</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>844-482-4812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Friedman, RN, BSN, OCN</last_name>
      <phone>703-636-1473</phone>
      <email>vcsclinicaltrials@usoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF inhibitor</keyword>
  <keyword>BRAF</keyword>
  <keyword>pan-RAF</keyword>
  <keyword>pan-RAF inhibitor</keyword>
  <keyword>RAF1</keyword>
  <keyword>ARAF</keyword>
  <keyword>BRAF alteration</keyword>
  <keyword>BRAF Class II</keyword>
  <keyword>BRAF Class III</keyword>
  <keyword>V600</keyword>
  <keyword>tumor growth inhibitor (TGI)</keyword>
  <keyword>melanoma</keyword>
  <keyword>NSCLC</keyword>
  <keyword>solid tumor</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>BRAF Class I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

